Syndax Pharmaceuticals (SNDX) Accumulated Expenses (2015 - 2026)

Syndax Pharmaceuticals' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $14.7 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 73.74% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (down 73.74% YoY), while the FY2025 annual figure was $19.0 million, up 31.08% from the prior year.
• Accumulated Expenses was $14.7 million for Q1 2026 at Syndax Pharmaceuticals, down from $19.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $71.1 million in Q2 2025 to a low of $1.9 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $23.3 million across 5 years, with a median of $14.7 million in 2026.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses surged 448.63% in 2023, then tumbled 73.74% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $14.4 million in 2022, then slipped by 22.28% to $11.2 million in 2023, then rose by 29.58% to $14.5 million in 2024, then soared by 31.08% to $19.0 million in 2025, then retreated by 22.55% to $14.7 million in 2026.
• The last three Accumulated Expenses figures came in at $14.7 million (Q1 2026), $19.0 million (Q4 2025), and $15.6 million (Q3 2025), per Business Quant data.